Topic: Sanofi-Aventis SA
(Reuters) - U.S. regulators on Monday revised the label for Sanofi SA's heart drug Multaq to reflect a doubling of health risks, including death, for some patients with irregular heart rhythms.In the updated label, the Food and Drug Administration said Multaq, known ...
Nov. 19--CHICAGO -- A heart drug that was the subject of a Journal Sentinel investigative report earlier this year has been linked to an increasing number of adverse side effects, according to an analysis by a watchdog group that monitors medication errors ...
STOCKHOLM (Reuters) - Sanofi-Aventis's recently launched heart rhythm drug Multaq should be considered as a treatment option for patients with atrial fibrillation, a common arrhythmia, according to new medical guidelines.Multaq, or dronedarone, was designed as a improvement on the older drug amiodarone. ...
The Steering Committee of the EXCLAIM study that explored the benefit of extended prophylaxis of venous thrombo embolism (VTE) with enoxaparin in acutely ill medical patients, announced today the publication of the comprehensive study results in the peer-reviewed journal Annals of Internal ...
SNY) announced today that the National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document (ACD)[1] for Multaq(R) (dronedarone) indicating its intention to recommend Multaq(R) use for the management of patients with ...
SNY), originator and manufacturer of Plavix and Iscover (clopidogrel hydrogen sulfate) confirms that all its clopidogrel-containing products, including Plavix and Iscover , are in full conformity with EMA requirements and are not concerned by the recall recommended yesterday by the European Medicines ...
BMY) today announced revisions to the U.S. prescribing information for PLAVIX (clopidogrel bisulfate), which include a boxed warning. The boxed warning concerns the diminished effectiveness of PLAVIX in patients who have a genetic variation leading to reduced formation of the active metabolite. ...
NEW YORK (Reuters Health) - About 3 million Americans suffer from the most common type of abnormal heart rhythm, atrial fibrillation, and that number is likely to double by 2035, new research shows.Atrial fibrillation occurs when the two upper chambers of the ...
SEPIA-ACS Multiple-Dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet -. SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 ...
SEPIA-ACS Multiple-Dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet -. SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 ...
From Around the Web
Video Gallery
-
Mergers & Acquisitions: Sanofi-Aventis SA Bids $18...
"Sanofi-Aventis (NYSE:SNY) making a hostile $18.5 billion bid ...2010-10-04 -
Sanofi-Aventis Seeking Suitor For US Dermatology ...
Sanofi-Aventis SA (NYSE:SNY), France's largest drug maker, is ...2011-04-14 -
SRS (SA) 2009 Sanofi-Aventis Prize Winner
Dr David Muchuweti Abdominal Surgical Site Infection: Risk factors and ...2010-02-04
